WO2003009855A3 - Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen - Google Patents

Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen Download PDF

Info

Publication number
WO2003009855A3
WO2003009855A3 PCT/EP2002/007986 EP0207986W WO03009855A3 WO 2003009855 A3 WO2003009855 A3 WO 2003009855A3 EP 0207986 W EP0207986 W EP 0207986W WO 03009855 A3 WO03009855 A3 WO 03009855A3
Authority
WO
WIPO (PCT)
Prior art keywords
delta
cells
organo
phosphorous compounds
activating gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/007986
Other languages
English (en)
French (fr)
Other versions
WO2003009855A2 (de
Inventor
Hassan Jomaa
Oliver Wolf
Boran Altincicek
Mathias Eberl
Martin Hintz
Ann-Kristin Kollas
Armin Reichenberg
Jochen Wiesner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioagency AG
Original Assignee
Bioagency AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26009714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003009855(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2001134705 external-priority patent/DE10134705A1/de
Priority claimed from DE2001135395 external-priority patent/DE10135395A1/de
Priority to AU2002339423A priority Critical patent/AU2002339423B2/en
Priority to DK02776913T priority patent/DK1408984T3/da
Priority to DE50212935T priority patent/DE50212935D1/de
Priority to KR1020047000770A priority patent/KR100906018B1/ko
Priority to JP2003515247A priority patent/JP4607451B2/ja
Application filed by Bioagency AG filed Critical Bioagency AG
Priority to EP02776913A priority patent/EP1408984B1/de
Priority to US10/484,143 priority patent/US7399756B2/en
Priority to CA2453817A priority patent/CA2453817C/en
Publication of WO2003009855A2 publication Critical patent/WO2003009855A2/de
Publication of WO2003009855A3 publication Critical patent/WO2003009855A3/de
Anticipated expiration legal-status Critical
Priority to US12/137,241 priority patent/US7871992B2/en
Priority to US13/007,852 priority patent/US20110112054A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3821—Acyclic saturated acids which can have further substituents on alkyl substituted by B, Si, P or a metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

In der vorliegenden Erfindung werden phosphororganische Verbindungen der allgemeinen Formel (I), deren Herstellung, deren Verwendungen zur Aktivierung von gamma/delta T-Zellen, zum Screening von Inhibitoren des GcpE und des LytB-Enzyms sowie zur Prophylaxe und zur Behandlung von Erkrankungen bei Mensch und Tier beschrieben.
PCT/EP2002/007986 2001-07-20 2002-07-18 Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen Ceased WO2003009855A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP02776913A EP1408984B1 (de) 2001-07-20 2002-07-18 Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
US10/484,143 US7399756B2 (en) 2001-07-20 2002-07-18 Organo-phosphorous compounds for activating gamma/delta T cells
DK02776913T DK1408984T3 (da) 2001-07-20 2002-07-18 Organofosforforbindelser til aktivering af gamma/delta T celler
CA2453817A CA2453817C (en) 2001-07-20 2002-07-18 Organophosphorus compounds for the activation of gamma/delta t-cells
DE50212935T DE50212935D1 (de) 2001-07-20 2002-07-18 Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
KR1020047000770A KR100906018B1 (ko) 2001-07-20 2002-07-18 감마/델타 ｔ세포 활성화를 위한 유기-인 화합물
JP2003515247A JP4607451B2 (ja) 2001-07-20 2002-07-18 ガンマ／デルタｔ細胞を活性化するための有機リン化合物
AU2002339423A AU2002339423B2 (en) 2001-07-20 2002-07-18 Organo-phosphorous compounds for activating gamma/delta T cells
US12/137,241 US7871992B2 (en) 2001-07-20 2008-06-11 Organophosphorous compounds for the activation of gamma/delta T cells
US13/007,852 US20110112054A1 (en) 2001-07-20 2011-01-17 Organophosphorous Compounds for the Activation of Gamma/Delta T Cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10134705.7 2001-07-20
DE2001134705 DE10134705A1 (de) 2001-07-20 2001-07-20 Organo-Phosphorverbindungen zur Aktivierung von gamma/delta-T-Zellen
DE2001135395 DE10135395A1 (de) 2001-07-25 2001-07-25 Organo-Phosphorverbindungen zur Aktivierung von gamma/delta-T-Zellen
DE10135395.2 2001-07-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10484143 A-371-Of-International 2002-07-18
US12/137,241 Continuation US7871992B2 (en) 2001-07-20 2008-06-11 Organophosphorous compounds for the activation of gamma/delta T cells

Publications (2)

Publication Number Publication Date
WO2003009855A2 WO2003009855A2 (de) 2003-02-06
WO2003009855A3 true WO2003009855A3 (de) 2003-11-06

Family

ID=26009714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007986 Ceased WO2003009855A2 (de) 2001-07-20 2002-07-18 Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen

Country Status (13)

Country Link
US (3) US7399756B2 (de)
EP (1) EP1408984B1 (de)
JP (1) JP4607451B2 (de)
KR (1) KR100906018B1 (de)
CN (1) CN1533279A (de)
AT (1) ATE411805T1 (de)
AU (1) AU2002339423B2 (de)
CA (1) CA2453817C (de)
DE (1) DE50212935D1 (de)
DK (1) DK1408984T3 (de)
ES (1) ES2315411T3 (de)
PT (1) PT1408984E (de)
WO (1) WO2003009855A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10201458A1 (de) * 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
ATE411805T1 (de) * 2001-07-20 2008-11-15 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
EP2359833A1 (de) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antivirale Phosphonatanaloga
CA2547008A1 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
US20100291118A1 (en) * 2003-12-02 2010-11-18 Innate Pharma Class of Gamma Delta T Cells Activators and Use Thereof
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
JP2007534743A (ja) 2004-04-26 2007-11-29 イネイト・ファーマ アジュバント組成物およびその使用方法
ME03423B (de) 2004-07-27 2020-01-20 Gilead Sciences Inc Phosphonat Analoga von HIV Inhibitor Verbindungen
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
BRPI0608926A2 (pt) * 2005-03-22 2010-11-03 Innate Pharma ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta
EP1924279A2 (de) * 2005-09-07 2008-05-28 The Secretary of State for Defence Adjuvans-vakzine
EP1933848A2 (de) * 2005-10-06 2008-06-25 Innate Pharma Phosphoantigen-salze von organischen basen und verfahren zu ihrer kristallisation
WO2008012538A2 (en) * 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20100029674A1 (en) 2006-11-17 2010-02-04 Innate Pharma, S.A. Methods of Using Phosphoantigen for the Treatment of Cancer
EP2123285A1 (de) 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosid-Phosphorantigene zur Verwendung in der VGAMMA9VDELTA2-T-Zellen-vermittelten Therapie
UA103329C2 (ru) 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
EP2324040B1 (de) 2008-09-10 2014-01-01 Innate Pharma Neue polymorphe form von chdmapp, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
GB0901423D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
WO2017011686A1 (en) * 2015-07-14 2017-01-19 University Of Iowa Research Foundation Fluorescent prodrugs
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
CN109651429A (zh) * 2017-10-11 2019-04-19 清华大学 高效稳定的Vγ9Vδ2 T细胞的小分子激动剂
WO2019118416A1 (en) * 2017-12-11 2019-06-20 The Procter & Gamble Company Phosphono-phosphate containing compounds and polymers
CN111432891B (zh) 2017-12-11 2024-01-02 宝洁公司 含膦酰基-磷酸根基团和阴离子基团的聚合物
WO2019118414A1 (en) 2017-12-11 2019-06-20 The Procter & Gamble Company Oral care compositions comprising phosphonate and anionic group containing polymers
CN111372554A (zh) 2017-12-11 2020-07-03 宝洁公司 包含多价阳离子和含膦酰基-磷酸根聚合物的组合物
US11198763B2 (en) 2017-12-11 2021-12-14 The Procter & Gamble Company Oral care compositions comprising phosphono-phosphate and anionic group containing polymers
CN111372553B (zh) 2017-12-11 2023-08-25 宝洁公司 制备含膦酰基-磷酸根的化合物的方法
WO2019182904A1 (en) 2018-03-19 2019-09-26 University Of Iowa Research Foundation Phosphonamidate butyrophilin ligands
WO2020065584A1 (en) 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030653A2 (de) * 1998-11-25 2000-06-02 Jomaa Pharmaka Gmbh Verwendung von phosphonoameisensäurederivaten zur behandlung von infektionen
WO2000059916A1 (fr) * 1999-04-06 2000-10-12 Institut National De La Sante Et De La Recherche Medicale Composes inhibitant selectivement les lymphocytes t gamma 9 delta 2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
WO1997043437A2 (en) * 1996-05-15 1997-11-20 The University Of Sheffield Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors
DE19828450A1 (de) 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
FR2782721B1 (fr) 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
ATE317007T1 (de) * 1998-09-22 2006-02-15 Bioagency Ag Gene des 1-desoxy-d-xylulose-biosynthesewegs
JP4025019B2 (ja) * 1999-01-21 2007-12-19 中外製薬株式会社 ２−メチル−３−ブテニル−１−ピロリン酸の塩およびリンパ球処理剤
WO2000072022A1 (de) * 1999-05-21 2000-11-30 Jomaa Pharmaka Gmbh Verwendung von genen des desoxy-d-xylulose-phosphatbiosynthesewegs zur veränderung der isoprenoidkonzentration
WO2001022816A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
DE10027821A1 (de) 2000-06-05 2001-12-06 Adelbert Bacher Der Mevalonat-unabhängige Isoprenoidbiosyntheseweg
ATE447017T1 (de) 2000-08-07 2009-11-15 Monsanto Technology Llc Am methyl-d-erythriol phosphat reaktionsweg beteiligte gene
DE10201458A1 (de) 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
DE10119905A1 (de) 2001-04-23 2002-10-24 Jomaa Pharmaka Gmbh Inaktivierung von Genen des MEP-Wegs
ATE411805T1 (de) * 2001-07-20 2008-11-15 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
WO2003038072A1 (en) 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030653A2 (de) * 1998-11-25 2000-06-02 Jomaa Pharmaka Gmbh Verwendung von phosphonoameisensäurederivaten zur behandlung von infektionen
WO2000059916A1 (fr) * 1999-04-06 2000-10-12 Institut National De La Sante Et De La Recherche Medicale Composes inhibitant selectivement les lymphocytes t gamma 9 delta 2

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BELMANT, C.; ET AL., THE FASEB JOURNAL, vol. 14, 2000, pages 1669 - 1670, XP002231963 *
BELMANT, CHRISTIAN ET AL: "3-Formyl-1-butyl pyrophosphate a novel mycobacterial metabolite-activatin human.gamma..delta. T cells", JOURNAL OF BIOLOGICAL CHEMISTRY (1999), 274(45), 32079-32084, XP002225541 *
ESPINOSA, E.;, THE JOURNAL OF IMMUNOLOGY, vol. 168, 2002, pages 6336 - 6343, XP002231966 *
FEURLE J.; ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 1, 2002, pages 148 - 154, XP002231965 *
FOX, D.T.; ET AL., J. ORG. CHEM., vol. 67, 2002, pages 5009 - 5010, XP002231970 *
GAO, W.; ET AL., ANGEW. CHEM. INT. ED, vol. 41, no. 14, 2002, pages 2604 - 2607, XP002231967 *
HINTZ, M.; ET AL., FEBS LETTERS, vol. 509, 2001, pages 317 - 322, XP002231964 *
JACOB L ET AL: "ON THE INFLUENCE OF PHOSPHORIC ESTER GROUPS IN GERANYLDIPHOSPHATE BIOSYNTHESIS", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, XX, XX, vol. 127, no. 6, 1990, pages 719 - 733, XP009003286 *
MCCLARD, R.W.; ET AL., J. AM. CHEM. SOC., vol. 109, 1987, pages 5544 - 5545, XP002231961 *
SEEMANN, M.; ET AL., TETRAHEDRON LETTERS, vol. 43, 2002, pages 1413 - 1415, XP002231968 *
SIRECI, G.; ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 1628 - 1635, XP002231962 *
TAKAGI ET AL., TETRAHEDRON LETTERS, vol. 41, 2000, pages 3395 - 3398, XP002225542 *
TANAKA Y ET AL: "Natural and synthetic non-peptide antigens recognized by human.gamma..delta. T cells", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 375, 11 May 1995 (1995-05-11), pages 155 - 158, XP002102418, ISSN: 0028-0836 *
WARD, J.L.; ET AL., J. CHEM. SOC., PERKIN TRANS. 1, 2002, pages 710 - 712, XP002231969 *

Also Published As

Publication number Publication date
JP2005508305A (ja) 2005-03-31
CA2453817A1 (en) 2003-02-06
US20060030546A1 (en) 2006-02-09
AU2002339423B2 (en) 2007-03-15
PT1408984E (pt) 2008-12-26
ATE411805T1 (de) 2008-11-15
WO2003009855A2 (de) 2003-02-06
EP1408984B1 (de) 2008-10-22
CA2453817C (en) 2011-09-20
KR100906018B1 (ko) 2009-07-06
JP4607451B2 (ja) 2011-01-05
US7871992B2 (en) 2011-01-18
DK1408984T3 (da) 2009-02-09
CN1533279A (zh) 2004-09-29
ES2315411T3 (es) 2009-04-01
KR20040030814A (ko) 2004-04-09
US20110112054A1 (en) 2011-05-12
AU2002339423C1 (en) 2003-02-17
EP1408984A2 (de) 2004-04-21
DE50212935D1 (de) 2008-12-04
US20080249067A1 (en) 2008-10-09
US7399756B2 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
NL300933I2 (nl) Letermovir
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2004094386A8 (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
ECSP055844A (es) Nuevos compuestos triciclicos
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
WO2004060878A3 (en) Inhibitors of phosphatases
WO2003024996A3 (de) Antibakterielle makrozyklen
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
TW200503672A (en) 2-aminobenzoyl derivatives
BR0112123A (pt) Composto
WO2004029019A3 (en) Compounds for the treatment of alzheimer’s disease
WO2004056762A3 (en) Novel aminobenzophenone compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VN ZA ZM ZW GH GM KE LS MW MZ SD SZ TZ UG ZM ZW AM

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2453817

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047000770

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028145585

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003515247

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002339423

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002776913

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002776913

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2006030546

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10484143

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10484143

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002339423

Country of ref document: AU